Studying resistance to IgA nephropathy treatments in real life
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You had a kidney biopsy after 2017 that confirmed IgA nephropathy
- You agree to allow your medical data to be used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study collects real-world information from people with IgA nephropathy who are being treated with one of two medicines, iptacopan or atrasentan. The goal is to understand how these treatments work in everyday practice, which may help improve care for others with the condition.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.